Share on LinkedInShare on LinkedIn

ARTICLE · 27 AUGUST 2015

Amgen And Apotex Do The Biosimilar Patent Dance

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex, Inc. infringes two of its patents.

United StatesIntellectual Property

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex, Inc. infringes two of its patents. Although several complaints have invoked the BPCIA, this may be the first one in which the patent dance provisions have been followed.

The Biosimilar Patent Dance

According to Amgen's complaint filed in the U.S. District Court for the Southern District of Florida, Apotex filed a Biologic License Application (BLA) seeking FDA approval to market a biosimilar version of Amgen's Neulasta® (pegfilgrastim) product. Amgen describes pegfilgrastim as "a recombinantly expressed, 175-amino acid form of ... human granulocyte-colony stimulating factor ('G-CSF') conjugated to a 20 kD monomethoxypolyethylene glycol (m-PEG) at the N-terminus."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from